ACE Research & CRScube to team up for African Clinical Studies

Africa’s clinical trial industry:Opportunities and key benefits for pharmaceutical and CRO sponsors

Global public health crises such as COVID 19, the Ebola virus, and emerging pathogens have intensified time to bring new vaccines and drugs to market. Furthermore, increasing regulatory requirements for diversity in clinical research require sponsors to consider international sites for pivotal trials.

Clinical trials are the mainstay of vaccine and drug development. Africa is an excellent option for Phase I - IV global health clinical trials. The number of clinical trials registered in Africa has tripled during the last decade.

Africa offers several benefits for sponsors. In this article, Dr. Amos Ndhere, Chief Medical Officer at ACE Research, an African niche full-service CRO providing early and late phase clinical trials services for the pharmaceutical, academic and non-profit research enterprises, cut through mumbo jumbo and emphasized the drivers of clinical research industry in Africa, and how sponsors can maximize clinical development ROI in Africa.

Share via

See CRScube in action

Book a demo

Explore how our platform will elevate your team and clinical trial management.

Get insights straight to your inbox

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

See all resources

Featured resources

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.

From our sales leaders Juan Munoz-Pujol and Scott Robertson

Why ICH E2B(R3) still matters in 2026 – A conversation with Ducksang (David) Im

While E2B(R3) standard has existed for some time, global adoption has been gradual. What makes 2026 critical is that many regulatory authorities worldwide have now finalized mandatory transitions.